Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

From there, the case for or against investing in Lilly should become much clearer. Eli Lilly's earnings report ...

So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays ...

(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 in ...

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related hospitalisations. Read more!

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

In recent years, GLP-1 agonist medications like Ozempic have gained notoriety for their weight loss effects and blood sugar regulation. However, these pharmaceuticals come with a host of potential ...

A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential for novel treatments pending further ...

GLP-1 receptor agonists (GLP-1 RAs) have the potential to negatively impact muscle mass because they can cause substantial weight loss, researchers have said. Previous studies have revealed that rapid ...

Subgroup analyses reveal GLP-1 RAs may reduce alcohol cravings and brain cue reactivity. Study: Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption ...

In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist resulted in higher week-72 rates of steatohepatitis resolution without worsening of liver fibrosis (63% vs 34% ...